Imagion Biosystems

Making strides in Bio-imaging and Nanotechnology with our proprietary MagSense™ and PrecisionMRX® products.

[Imagion Biosystems @imagionbio]

Thank you @StockheadAU, for the coverage on our extended collaboration with Siemens Healthineers! We're excited to move forward into our Phase 2 trials with their support. Watch the full video below.

[Stockhead @StockheadAU]

.@imagionbio $IBX has strengthened its partnership with Siemens for the next stage of clinical testing on its MagSense cancer imaging technology.
https://t.co/pelwClEpQd

[Imagion Biosystems @imagionbio]

We're excited to announce we've extended our collaboration with @SiemensHealth to support the upcoming MagSense® HER2 Phase 2 trial, bringing their MRI expertise alongside our molecular imaging technology. $IBX

Read the full announcement: https://t.co/TYC354VWuY

[Imagion Biosystems @imagionbio]

Thank you @StockheadAU, for the coverage on the firm commitments secured through our capital raise! We're excited to see what this next chapter holds for IBX.
Watch the full video below.

[Stockhead @StockheadAU]

Tylah Tully looks at Imagion Biosystems (@imagionbio) and the firm commitments received for $3.75m to begin a Phase 1B/2 clinical trial in the US for its MagSense HER2 imaging agent for treatment of breast cancer. $IBX https://t.co/vSMAG3Vmxm

[Imagion Biosystems @imagionbio]

We're excited to announce that we have secured firm commitments for AU$3.75M in new capital following the FDA’s clearance of our IND application for a Phase 2 clinical trial.

Read the full announcement: https://t.co/5I6mwxIvpm

[Imagion Biosystems @imagionbio]

The WHO estimates over 35M new cancer cases globally in 2050. Following IND clearance from the FDA, we're continuing development of our MagSense molecular MRI technology, aiming to enhance cancer detection and help patients get the right care sooner.

(https://t.co/0OEGi9EdLM)

[Imagion Biosystems @imagionbio]

Following our milestone IND clearance from the FDA, we will be giving an update presentation at the June 10th Emerging Growth Conference. Register for the conference here: https://t.co/neCvSYPOoG

[Imagion Biosystems @imagionbio]

Thank you @ausstockchick for highlighting this exciting news. We're thankful for the support from our investors and look forward to sharing more updates as we advance into Phase 1b/2 clinical trials.

[that stock chick @ausstockchick]

A little background on the lastest @imagionbio ASX IBX announcement.

It's a pretty big milestone.

#stocks #ASX #biotech

[Imagion Biosystems @imagionbio]

“(Imagion) has secured IND clearance from the FDA in an achievement that is the company’s most important to date…”  
Click the link to read Pitt Street Research’s recent "flash note" and learn why they think this is such a pivotal milestone: https://t.co/sU5Px0KfCW

[Imagion Biosystems @imagionbio]

Thank you @StockheadAU for bringing attention to this important regulatory milestone. We are looking forward to moving into 1b/2 clinical trials soon! Read the full article here: https://t.co/rV0jbf9Mmx

[Stockhead @StockheadAU]

Imagion Biosystems (@imagionbio) has received clearance from the US Food and Drug Administration (FDA) to proceed with a Phase 1b/2 clinical trial of its MagSense HER2+ Imaging Agent in patients with HER2+ breast cancer. #ASX $IBX

🔗 Read more: https://t.co/EE95Ub0CJZ

[Imagion Biosystems @imagionbio]

Thank you @ausstockchick for highlighting this important regulatory milestone as we move into Phase 1b/2 clinical trials in HER2+ breast cancer patients. We are excited to continue this important work.

[that stock chick @ausstockchick]

$IBX re-rate alert!!

Imagion receives written notice from the US Food and Drug Administration clearing the IND for MagSense®
HER2 Imaging Agent and allowing the Phase 1b/2 clinical trial in HER2+ breast cancer patients to proceed!!

$IBX is dedicated to better and more accurate detection of cancer and this milestone should be celebrated.

#biotech #stocks

[Imagion Biosystems @imagionbio]

We are excited to announce that the U.S. FDA has issued a Study May Proceed notice for our IND application. Clearance to advance to our Phase 2 study underscores the safety and veracity of the trial and marks a major milestone for the Company.
$IBX #MagSense #MolecularMRI

[Imagion Biosystems @imagionbio]

Yesterday, we held our 2026 Annual General Meeting, where Executive Chairman Bob Proulx addressed shareholders on a year of meaningful progress.

An updated investor presentation has been lodged with the ASX. Review it here: https://t.co/PwfE0DWjPd

[Imagion Biosystems @imagionbio]

A study in Radiology (RSNA) found 62% of ovarian lesions flagged as likely malignant on ultrasound were benign. Where early detection is critical for ovarian cancer survival, MagSense® is designed to offer molecular-level diagnostic precision.

Read more: https://t.co/4MYROI6Wyd

[Imagion Biosystems @imagionbio]

May is National Cancer Research and Women's Health Month. In 2026, an estimated 322,000 US women will be diagnosed with breast cancer (https://t.co/P2PlikhEn1). Our MagSense® technology aims to detect cancer with greater precision, providing clearer answers earlier.

[Imagion Biosystems @imagionbio]

Happy #InternationalWomensDay!
We're working toward a future where women facing a cancer diagnosis get the clarity and certainty they deserve.
Today we celebrate the women who inspire us, fight for us and keep pushing the world forward.
#IWD2026 #MolecularMRI $IBX

[Imagion Biosystems @imagionbio]

We've lodged our Appendix 4E and 2025 Annual Report with the ASX. Read the full report on our Investor Hub: https://t.co/Rs0jVCQ3vB
$IBX #MolecularMRI

[Imagion Biosystems @imagionbio]

Thank you to everyone who joined us at the @EmergingGrowthC this week where we shared our latest MagSense® molecular MRI progress. $IBX
Watch the full presentation: https://t.co/ZucDYKZ6Sm

[Imagion Biosystems @imagionbio]

"This is a new class of imaging agents for MRI." - Executive Chairman Bob Proulx discusses how MagSense® aims to bring molecular specificity to cancer detection in the latest @TheMarketBullAU Interview.
Watch full interview: https://t.co/yh4ZzCXrqG
$IBX #CancerDetection #MRI

[Imagion Biosystems @imagionbio]

Pitt Street Research examines $IBX molecular MRI tech ahead of Phase II trials.
Report covers MagSense® competitive advantages, trial design and commercialization pathway.
Read the full analysis: https://t.co/BPCgroAvPO
#Biotech #MedTech

[Imagion Biosystems @imagionbio]

February is Ovarian Cancer Awareness Month in Australia. Where biopsy options are limited, molecular MRI technology aims to provide the molecular specificity needed for earlier, more confident detection. $IBX
Discover more: https://t.co/lOzfem7OxO